Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRITON-PN
2025-522544-40-00Phase 3Authorised
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Mar 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 22
01
Overview
Phase 3, randomised, open-label trial of nucresiran in hereditary transthyretin amyloidosis (hATTR) (3 arms), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Change from baseline in Modified Neuropathy Impairment Score +7. Planned start Mar 2026; status: authorised.
02
Drugs
nucresiran
03
Conditions
hereditary transthyretin amyloidosis (hATTR)
Beyond the preview
Go deeper on 2025-522544-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522544-40-00.